NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Ace Therapeutics' Custom Hemorrhagic Stroke Research Models and Services
TL;DR
Ace Therapeutics offers customized hemorrhagic stroke models that give researchers a competitive edge in accelerating the development of life-saving treatments through precise preclinical testing.
Ace Therapeutics provides both in vitro and in vivo hemorrhagic stroke models, including hemoglobin, hemin, and whole blood injection models, each designed to replicate specific disease mechanisms for targeted research.
Ace Therapeutics' research models help advance treatments for hemorrhagic stroke, potentially reducing its devastating impact and improving patient outcomes worldwide through better therapeutic development.
Ace Therapeutics uses innovative models like microballoon insertion to simulate brain pressure changes, offering researchers unique tools to study stroke mechanisms in detail.
Found this article helpful?
Share it with your network and spread the knowledge!
Ace Therapeutics is an industry leader in preclinical stroke research services that provides customized hemorrhagic stroke models and CRO services to empower researchers worldwide to study intracerebral hemorrhage (ICH) and accelerate treatment development.
ICH has devastating impact with intricate pathophysiology including hematoma expansion, neuronal cell death, oxidative stress, blood-brain barrier disruption, and neuroinflammation, so preclinical models that accurately replicate these key disease mechanisms are indispensable for developing effective treatments.
Ace Therapeutics offers three main in vitro ICH models: hemoglobin models for studying hematoma expansion and iron dynamics, hemin models for mimicking secondary injury pathways like BBB disruption and neuroinflammation, and autologous blood models for replicating the full hemotoxicity of ICH.
Ace Therapeutics offers whole blood injection models (gold standard for mimicking acute hematoma accumulation), collagenase models (inducing hemorrhage via microvascular rupture), and microballoon insertion models (simulating space-occupying effects of ICH) across multiple species including rodents and large animals.
Ace Therapeutics' team collaborates with researchers to select the optimal model based on study goals, whether focusing on acute vs. chronic hematoma phases, molecular vs. hemodynamic analysis, or efficacy testing, with each model optimized to address distinct research questions.
Their in vitro ICH models simplify complex biological systems while retaining critical disease-relevant features, making them ideal for high-throughput screening and targeted pathway research, with each model optimized to isolate and analyze targeted mechanisms without confounding variables.
Whole blood injection models allow precise control of hematoma volume and are widely used to evaluate interventions for swelling, hematoma expansion, and hemodynamic changes, closely replicating clinical ICH's rapid blood accumulation in both small and large animals.
You can visit their website for more information on customized hemorrhagic stroke models, in vitro ICH models, and ICH animal model CRO services.
Curated from 24-7 Press Release
